Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹260Cr
Finance - Investment/Others
Rev Gr TTM
Revenue Growth TTM
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

FUNDVISER
VS
| Quarter | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | | | | 42,400.0 | 1,11,125.0 | 676.5 |
| 0 | 0 | 4 | 26 | 16 | 44 | 49 |
Operating Profit Operating ProfitCr |
| -100.0 | -250.0 | 32.7 | 2.1 | 4.8 | 0.1 | 5.4 |
Other Income Other IncomeCr | 0 | 0 | 1 | -1 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 3 | 0 | 1 | 0 | 3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 |
|
Growth YoY PAT Growth YoY% | | | | | 3,833.3 | -742.9 | -41.0 |
| -75.0 | -175.0 | 48.7 | -1.7 | 6.6 | -1.3 | 3.7 |
| -0.1 | -0.1 | 6.3 | -0.9 | 1.9 | -1.0 | 3.2 |
| Financial Year | Mar 2025 | TTM |
|---|
|
| | 318.9 |
| 31 | 135 |
Operating Profit Operating ProfitCr |
| 7.7 | 3.0 |
Other Income Other IncomeCr | 0 | -1 |
Interest Expense Interest ExpenseCr | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 |
| 3 | 3 |
| 0 | 1 |
|
| | -26.1 |
| 8.0 | 1.4 |
| 5.2 | 3.2 |
| Financial Year | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 5 | 6 |
| 15 | 19 |
Current Liabilities Current LiabilitiesCr | 29 | |
Non Current Liabilities Non Current LiabilitiesCr | 0 | |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 39 | |
Non Current Assets Non Current AssetsCr | 16 | |
Total Assets Total AssetsCr |
| Financial Year | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -10 |
Investing Cash Flow Investing Cash FlowCr | -9 |
Financing Cash Flow Financing Cash FlowCr | 14 |
|
Free Cash Flow Free Cash FlowCr | -10 |
| -380.8 |
CFO To EBITDA CFO To EBITDA% | -394.4 |
| Financial Year | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 76 |
Price To Earnings Price To Earnings | 28.4 |
Price To Sales Price To Sales | 2.3 |
Price To Book Price To Book | 3.8 |
| 31.3 |
Profitability Ratios Profitability Ratios |
| 100.0 |
| 7.7 |
| 8.0 |
| 10.8 |
| 13.3 |
| 4.9 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Fundviser Capital (India) Limited (BSE: **530197**) is a diversified financial services and investment holding company. Originally established as a manufacturer of dye intermediates, the company underwent a transformative pivot in **FY 2015-16** following the divestment of its industrial assets. Under new leadership since a **2023** change in control, the firm has evolved into a multi-sector investment vehicle, deploying capital into high-growth subsidiaries, real estate, and global trading markets.
---
### **Strategic Evolution & Corporate Governance**
The company’s trajectory is defined by a complete management overhaul and a shift toward aggressive capital deployment.
* **Change in Control (2023):** Following a Share Purchase Agreement and an Open Offer at **₹18.00** per share, **Mrs. Kriti Jain** and **Mr. Sohan Lal Garg** assumed promoter status.
* **Leadership Team:** **Mr. Prem Krishan Jain** serves as Chairman and Managing Director (re-appointed **September 2025**), supported by **Mrs. Kriti Jain** as Whole Time Director (appointed **April 2025**).
* **Identity Rebranding:** Reflecting its new focus, the Corporate Identification Number (CIN) was updated to **L64300MH1985PLC205386** in **December 2025**.
* **Promoter Stability:** As of the latest filings, the promoter group maintains a robust **66.36%** equity stake, ensuring strong alignment with shareholder interests.
---
### **Capital Structure & Fundraising Trajectory**
Fundviser has significantly expanded its equity base to provide the "dry powder" necessary for its acquisition-led growth strategy.
* **Authorized Capital Expansion:** Increased from **₹3.75 Crore** to **₹12.50 Crore** between **2024** and **2025**.
* **Preferential Allotment (2025):** The company issued **64,85,000** Convertible Warrants at **₹122.50** per warrant (including a premium of **₹112.50**), targeting a total raise of **₹79.44 Crore**.
* **Warrant Conversion (March 2026):** The Board approved the allotment of **19,85,000** Equity Shares following the conversion of warrants by promoters and strategic investors, who paid the remaining **75%** of the issue price (**₹91.875** per warrant).
* **Listed Capital Growth:** Following these conversions, the listed share capital reached **₹5.15 Crore** in **October 2024** and further increased to **₹7.90 Crore** (comprising **79,00,000** shares) by **March 2026**.
---
### **Diversified Subsidiary Portfolio & Global Expansion**
The company operates as a holding entity, managing a portfolio of subsidiaries across entertainment, infrastructure, and international trade.
| Subsidiary / Entity | Stake | Sector | Key Activity |
| :--- | :---: | :--- | :--- |
| **Starlight Box Theatres Pvt Ltd** | **51.61%** | Entertainment | Container box cinemas; film production/distribution. |
| **DARS Transtrade Pvt Ltd** | **51.12%** | Trading/Logistics | General trading and construction services. |
| **New India RE & INFRA LLP** | **64.00%** | Real Estate | Infrastructure development (Inc. Oct 2024). |
| **Silver Sage Trading LLC (UAE)** | **100.00%** | Global Trade | International trading of commodities, scrap, and electronics. |
**Key Developments:**
* **International Entry:** In **February 2026**, the company initiated the **100%** acquisition of **Silver Sage Trading LLC (UAE)** for **₹1.25 Crore**, marking its first foray into the Middle Eastern commodity markets.
* **Niche Entertainment:** Through **Starlight Box Theatres**, the company is scaling a unique "container cinema" model, which reported a high **26.94% PAT margin** in **FY 2024-25**.
* **New Verticals:** In **October 2025**, the Main Object Clause was amended to include trading in **precious metals (gold, silver, bullion)** and electronics. The company is also evaluating entries into **Distilleries** and **Patented Medical Devices**.
---
### **Financial Performance & Asset Deployment**
Fundviser has successfully transitioned from a loss-making entity to a profitable investment firm.
#### **Standalone Financial Highlights (INR Hundreds)**
| Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 |
| :--- | :--- | :--- | :--- |
| **Revenue from Operations** | **1,94,118** | **96,520** | **21,141** |
| **Other Income** | **22,591** | **850** | **1,055** |
| **Net Profit / (Loss)** | **43,080** | **44,337** | **(1,009)** |
#### **Consolidated Group Performance**
For the nine months ended **December 31, 2025**, the group reported:
* **Total Revenue:** **₹107.73 Crore**
* **Net Profit After Tax (PAT):** **₹1.17 Crore**
**Operational Limits:** To facilitate aggressive growth, shareholders approved an investment limit for loans, guarantees, and securities up to an aggregate of **₹150 Crore**.
---
### **Risk Management & Governance Framework**
The company maintains a formal risk governance structure to mitigate exposures inherent in financial services.
* **Credit & Liquidity Risk:** Funds are held exclusively with **Public Sector Banks**. The company maintains **committed credit lines** and utilizes rolling cash flow forecasts to ensure liquidity stability.
* **Market & Equity Price Risk:** The company is exposed to volatility in its quoted investments, which had a fair value of **₹68,88,697** as of **March 31, 2025**. A **10% market shift** would impact equity by approximately **₹6.88 Lakhs**.
* **Audit Observations:** Auditors have flagged the **Valuation of Unlisted Investments** as a **Key Audit Matter**, noting the high degree of management judgment involved.
* **Regulatory Compliance:** The company is committed to maintaining the **Minimum Public Shareholding (MPS)** of **25%** as per **SEBI (LODR)** regulations. The promoters have undertaken to dilute their holdings if corporate actions trigger a breach of this limit.
* **Subsidiary Transparency:** Investors should note that **DARS Transtrade** carries significant **Trade Receivables (₹15.09 Crore)**, and **New India RE & Infra LLP** is currently in a pre-revenue stage despite having reported trade payables.